ECO PINE NF

Informasi Utama

  • Nama dagang:
  • ECO PINE NF
  • Digunakan untuk:
  • manusia
  • Jenis Obat:
  • Perangkat medis

Dokumen

  • untuk masyarakat umum:
  • Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.


    Meminta selebaran informasi untuk masyarakat umum.

Lokalisasi

  • Tersedia di:
  • ECO PINE NF
    Indonesia
  • Bahasa:
  • Bahasa Indonesia

Informasi lainnya

Status

  • Sumber:
  • Ecolab
  • Nomor Otorisasi:
  • 907519
  • Pembaharuan Terakhir:
  • 12-03-2018

Ringkasan karakteristik Produk: dosis, interaksi, efek samping

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

1 / 9

BAGIAN 1. IDENTIFIKASI SENYAWA (TUNGGAL ATAU CAMPURAN)

Nama Produk

ECO PINE NF

Cara identifikasi lainnya

Tidak berlaku.

Penggunaan yang dianjurkan

Pembersih Lantai

Informasi pengenceran

produk

0.75 % - 2.3 %

Perusahaan

PT. Ecolab International Indonesia

Jl. Jababeka XII.B Kav V-37

Kawasan Industri Jababeka, Cikarang Indonesia 17530

(62-21) 8983 4891

Nomor telepon darurat

+1-651-222-5352 (Amerika Syarikat)

Tanggal penerbitan pertama

11.08.2016

BAGIAN 2. IDENTIFIKASI BAHAYA

Klasifikasi GHS

Produk TERJUAL

Korosi/iritasi kulit

Kategori 2

Kerusakan mata serius/iritasi

pada mata

Kategori 2A

Toksisitas akuatik kronis

Kategori 3

Penggunaan produk dicairkan

Bukan merupakan zat atau campuran yang berbahaya.

Elemen label GHS

Produk TERJUAL

Piktogram bahaya

Kata sinyal

Awas

Pernyataan Berbahaya

Menyebabkan iritasi kulit.

Menyebabkan iritasi mata yang serius.

Berbahaya pada kehidupan perairan dengan efek jangka panjang.

Pernyataan Hati-hati

Pencegahan:

Cuci kulit dengan seksama setelah menangani. Hindarkan pelepasan

ke lingkungan. Kenakan sarung tangan/ pelindung mata/ pelindung

wajah.

Respons:

JIKA TERKENA KULIT: Cucilah dengan air yang banyak. JIKA

TERKENA MATA : Bilas dengan seksama dengan air untuk beberapa

menit. Lepaskan lensa kontak jika memakainya dan mudah

melakukannya.Lanjutkan membilas. Jika terjadi iritasi pada kulit: Cari

pertolongan medis. Jika iritasi mata tidak segera sembuh: Cari

pertolongan medis.

Pembuangan:

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

2 / 9

Buang isi / wadah ke tempat pembuangan limbah yang disetujui.

Penggunaan produk dicairkan

Pernyataan Hati-hati

Pencegahan:

Cucilah tangan bersih-bersih setelah menangani.

Respons:

Dapatkan nasehat/perhatian medis jika kamu merasa tidak sehat.

Penyimpanan:

Simpan sesuai dengan peraturan setempat.

Produk TERJUAL

Bahaya lain

Tidak ada yang diketahui.

BAGIAN 3. KOMPOSISI/INFORMASI TENTANG BAHAN PENYUSUN

Produk TERJUAL

Bahan/preparasi murni

Campuran

Nama kimia

No-CAS

Konsentrasi (%)

Fattyalcohol ethoxylates > 5EO

68551-12-2

1 - 5

BENZIL-(C12-C16 ALKIL)-DIMETIL-AMONIUM

KLORIDA

68424-85-1

1 - 5

Penggunaan produk dicairkan

Tidak ada zat berbahaya

BAGIAN 4. TINDAKAN PERTOLONGAN PERTAMA PADA KECELAKAAN

Produk TERJUAL

Jika kontak dengan mata

Basuhlah segera dengan banyak air, dan berikan air sebanyak-

banyaknya di bawah kelopak mata, sekurangnya selama 15 menit.

Lepas lensa kontak, jika digunakan dan mudah melakukannya.

Lanjutkan membilas. Cari dan dapatkan bantuan medis.

Jika kontak dengan kulit

Segera cuci bersih dengan banyak air sedikitnya selama 15 menit.

Gunakan sabun lunak bila tersedia. Tangani secara medis jika terjadi

iritasi dan iritasi tidak kunjung hilang.

Jika tertelan

Bilas mulut. Tangani secara medis jika muncul gejala.

Jika terhirup

Tangani secara medis jika muncul gejala.

Perlindungan aiders pertama

Bila ada bahaya kontaminasi lihat bab 8 tentang perlengkapan

melindungi diri.

Instruksi kepada dokter

Tangani menurut gejala.

Gejala dan efek yang paling

penting, baik yang akut

maupun yang tertunda

Lihat bagian 11 untuk informasi yang lebih terperinci mengenai

berbagai efek dan gejala pada kesehatan.

Penggunaan produk dicairkan

Jika kontak dengan mata

Bilas dengan banyak air.

Jika kontak dengan kulit

Bilas dengan banyak air.

Jika tertelan

Bilas mulut. Tangani secara medis jika muncul gejala.

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

3 / 9

Jika terhirup

Tangani secara medis jika muncul gejala.

BAGIAN 5. TINDAKAN PEMADAMAN KEBAKARAN

Produk TERJUAL

Media pemadam yang sesuai

Gunakan tindakan pemadaman kebakaran yang sesuai untuk situasi

lokal dan lingkungan sekitar.

Zat pemadam kebakaran

yang tidak sesuai

Tidak ada yang diketahui.

Bahaya spesifik yang

diakibatkan bahan kimia

tersebut

Tidak mudah-menyala atau terbakar.

Produk pembakaran

berbahaya

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

Alat pelindung khusus bagi

petugas pemadam

kebakaran

Gunakan alat pelindung diri.

Metode pemadaman khusus

Residu kebakaran dan air bekas pemadam kebakaran yang tercemar

harus dibuang sesuai dengan peraturan lokal. Jika terjadi kebakaran

dan/atau ledakan, jangan menghirup asap.

BAGIAN 6. TINDAKAN PENANGGULANGAN JIKA TERJADI TUMPAHAN DAN KEBOCORAN

Produk TERJUAL

Tindakan pencegahan

pribadi, peralatan pelindung

dan prosedur darurat

Pastikan agar pembersihan dilakukan hanya oleh petugas terlatih.

Mengaculah pada langkah-langkah perlindungan yang dicantumkan

dalam seksi 7 dan 8.

Tindakan pencegahan untuk

melindungi lingkungan

Jangan sampai mengenai tanah, air permukaan atau air tanah.

Metode dan bahan untuk

penyimpanan dan

pembersihan

Hentikan kebocoran jika aman untuk melakukannya.Tahan dan

kumpulkan tumpahan dengan bahan penyerap yang tidak mudah

terbakar (misalnya pasir, tanah, tanah diatomaceus, vermiculite) dan

tempatkan dalam kontener untuk dibuang berdasarkan peraturan

lokal/nasional (lihat seksi 13).Siramlah sisa-sisa dengan air.Untuk

tumpahan dalam jumlah banyak, bendung tumpahan bahan atau

tumpahan yang mengandung bahan materi untuk memastikan agar

tidak mengalir menuju saluran air.

Penggunaan produk dicairkan

Tindakan pencegahan

pribadi, peralatan pelindung

dan prosedur darurat

Mengaculah pada langkah-langkah perlindungan yang dicantumkan

dalam seksi 7 dan 8.

Tindakan pencegahan untuk

melindungi lingkungan

Tidak diperlukan tindakan pencegahan khusus untuk melindungi

lingkungan.

Metode dan bahan untuk

penyimpanan dan

Hentikan kebocoran jika aman untuk melakukannya.Tahan dan

kumpulkan tumpahan dengan bahan penyerap yang tidak mudah

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

4 / 9

pembersihan

terbakar (misalnya pasir, tanah, tanah diatomaceus, vermiculite) dan

tempatkan dalam kontener untuk dibuang berdasarkan peraturan

lokal/nasional (lihat seksi 13).Siramlah sisa-sisa dengan air.Untuk

tumpahan dalam jumlah banyak, bendung tumpahan bahan atau

tumpahan yang mengandung bahan materi untuk memastikan agar

tidak mengalir menuju saluran air.

BAGIAN 7. PENANGANAN DAN PENYIMPANAN

Produk TERJUAL

saran penanganan yang

aman

Jangan sampai kena kulit dan mata. Cucilah tangan bersih-bersih

setelah menangani.

Kondisi untuk penyimpanan

yang aman

Jauhkan dari jangkauan anak-anak. Jaga wadah tertutup rapat.

Simpan dalam wadah yang berlabel sesuai.

Suhu penyimpanan

0 °C ke 50 °C

Penggunaan produk dicairkan

saran penanganan yang

aman

Cucilah tangan setelah menangani. Untuk perlindungan pribadi lihat

seksi 8.

Kondisi untuk penyimpanan

yang aman

Jauhkan dari jangkauan anak-anak. Jaga wadah tertutup rapat.

Simpan dalam wadah yang berlabel sesuai.

BAGIAN 8. KONTROL PAPARAN/ PERLINDUNGAN DIRI

Produk TERJUAL

Komponen dengan parameter pengendalian di tempat kerja

Tidak mengandung bahan-bahan yang mempunyai nilai batas eksposur pekerjaan.

Pengendalian teknik yang

sesuai

Ventilasi umum yang baik semestinya cukup untuk mengendalikan

pemaparan pekerja terhadap kadar kontaminasi yang terbawa-udara.

Alat Pelindung Diri

Perlindungan mata

Kacamata-pengaman berpelindung-samping

Perlindungan tangan

Kenakan perlengkapan perlindungan pribadi berikut ini:

Jenis sarung tangan standar.

Sarung tangan harus dibuang atau diganti apabila terdapat indikasi

mengalami degradasi atau kebocoran kimia.

Perlindungan kulit

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan pernapasan

Biasanya tidak diperlukan alat bantu pelindung pernapasan pribadi.

Tindakan higienis

Tangani sesuai dengan praktik kebersihan dan keselamatan industri

yang baik. Cuci muka, tangan dan kulit yang terpapar dengan

seksama setelah menangani.

Penggunaan produk dicairkan

Pengendalian teknik yang

sesuai

Ventilasi umum yang baik semestinya cukup untuk mengendalikan

pemaparan pekerja terhadap kadar kontaminasi yang terbawa-udara.

Alat Pelindung Diri

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

5 / 9

Perlindungan mata

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan tangan

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan kulit

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan pernapasan

Biasanya tidak diperlukan alat bantu pelindung pernapasan pribadi.

BAGIAN 9. SIFAT FISIKA DAN KIMIA

Produk TERJUAL

Penggunaan produk dicairkan

Tampilan

: cair

cair

Warna

: bening, kuning-kecoklatan

Tanpa-warna

: seperti fenol

seperti fenol

9.0 - 12.5, 100 %

9.0 - 11.0

Titik nyala

Tidak berlaku.

Ambang Bau

Data tidak tersedia

Titik lebur/titik beku

Data tidak tersedia

Titik didih awal/rentang didih

> 100 °C

Laju penguapan

Data tidak tersedia

Flamabilitas (padatan, gas)

Data tidak tersedia

Tertinggi batas ledakan

Data tidak tersedia

Terendah batas ledakan

Data tidak tersedia

Tekanan uap

Data tidak tersedia

Kerapatan (densitas) uap

relatif

Data tidak tersedia

Berat jenis relatif

1.0 - 1.01

Kelarutan dalam air

larut

Kelarutan dalam pelarut lain

Data tidak tersedia

Koefisien partisi (n-

oktanol/air)

Data tidak tersedia

Suhu dapat membakar

sendiri (auto-ignition

temperature)

Data tidak tersedia

Dekomposisi termal

Data tidak tersedia

Viskositas, kinematis

84.729 mm2/s (40 °C)

Sifat peledak

Data tidak tersedia

Sifat oksidator

Data tidak tersedia

Berat Molekul

Data tidak tersedia

Data tidak tersedia

BAGIAN 10. STABILITAS DAN REAKTIFITAS

Produk TERJUAL

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

6 / 9

Stabilitas kimia

Stabil pada kondisi normal.

Kemungkinan reaksi

berbahaya

Tidak ada reaksi berbahaya yang diketahui dalam kondisi

penggunaan normal.

Kondisi yang harus dihindari

Tidak ada yang diketahui.

Bahan non-kompatibel

Asam

Basa

Bahan organik

Produk berbahaya hasil

peruraian

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

BAGIAN 11. INFORMASI TOKSIKOLOGI

Informasi tentang rute

paparan

Penghirupan, Kena mata, Kena kulit

Kemungkinan Dampak Kesehatan

Produk TERJUAL

Mata

Menyebabkan iritasi mata yang serius.

Kulit

Menyebabkan gangguan pada kulit.

Tertelan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penghirupan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Eksposur Kronis

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penggunaan produk dicairkan

Mata

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Kulit

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Tertelan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penghirupan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Eksposur Kronis

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Pengalaman dengan paparan pada manusia

Produk TERJUAL

Kena mata

Kemerahan, Nyeri, Iritasi

Kena kulit

Kemerahan, Iritasi

Tertelan

Tidak ada gejala yang diketahui atau diperkirakan.

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

7 / 9

Penghirupan

Tidak ada gejala yang diketahui atau diperkirakan.

Penggunaan produk dicairkan

Kena mata

Tidak ada gejala yang diketahui atau diperkirakan.

Kena kulit

Tidak ada gejala yang diketahui atau diperkirakan.

Tertelan

Tidak ada gejala yang diketahui atau diperkirakan.

Penghirupan

Tidak ada gejala yang diketahui atau diperkirakan.

Toksisitas

Produk TERJUAL

Produk

Toksisitas oral akut

: Perkiraan toksisitas akut : > 5,000 mg/kg

Toksisitas inhalasi akut

: 4 h Perkiraan toksisitas akut : 25.64 mg/l

Toksisitas kulit akut

: Perkiraan toksisitas akut : > 5,000 mg/kg

Kerusakan/gangguan kulit

Data tidak tersedia

Gangguan mata/kerusakan

mata serius

Data tidak tersedia

Sensitisasi sistem

pernafasan atau kulit

Data tidak tersedia

Karsinogenisitas

Data tidak tersedia

Pengaruh pada alat

reproduksi

Data tidak tersedia

Mutagenitas sel germinal

Data tidak tersedia

Teratogenisitas

Data tidak tersedia

STOT - paparan tunggal

Data tidak tersedia

STOT - paparan berulang

Data tidak tersedia

Derajat keracunan melalui

pernapasan

Data tidak tersedia

BAGIAN 12. INFORMASI EKOLOGI

Produk TERJUAL

Derajat racun bagi lingkungan (ekotoksisitas)

Dampak lingkungan

Berbahaya pada kehidupan perairan dengan efek jangka panjang.

Produk

Keracunan untuk ikan

: Data tidak tersedia

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: Data tidak tersedia

Keracunan untuk ganggang

: Data tidak tersedia

Komponen

Keracunan untuk ikan

: Fattyalcohol ethoxylates > 5EO

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

8 / 9

96 h LC50 Ikan: 1.5 mg/l

Komponen

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: BENZIL-(C12-C16 ALKIL)-DIMETIL-AMONIUM KLORIDA

48 h EC50 Daphnia magna (Kutu air): 0.016 mg/l

Ketahanan dan tingkat penguraian

Produk TERJUAL

Biodegradabel

Potensi penumpukan biologis

Data tidak tersedia

Mobilitas di dalam tanah

Data tidak tersedia

Dampak merugikan lainnya

Data tidak tersedia

BAGIAN 13. PERTIMBANGAN PEMBUANGAN/ PEMUSNAHAN

Produk TERJUAL

Metode pembuangan

Jika mungkin, pendauran-ulang lebih disukai daripada pembuangan

atau pembakaran. Jika proses daur-ulang tidak praktis, buang sesuai

dengan peraturan lokal. Buanglah sampah dalam fasilitas

pembuangan sampah yang disetujui.

Produk tidak boleh sampai memasuki saluran pembuangan, sungai,

danau dsb. atau tanah.

Pembuangan limbah

Buang sebagai produk yang tidak digunakan. Wadah kosong harus

dibawa ke tempat penanganan limbah yang telah disetujui untuk

didaur-ulang atau dibuang. Dilarang menggunakan kembali

kemasan/wadah yang sudah kosong. Buanglah sesuai dengan

peraturan lokal, negara bagian, dan federal.

Penggunaan produk dicairkan

Metode pembuangan

Produk diencerkan dapat disalurkan ke saluran pembuangan sanitasi

Pembuangan limbah

Buanglah sesuai dengan peraturan lokal, negara bagian, dan federal.

BAGIAN 14. INFORMASI PENGANGKUTAN

Produk TERJUAL

Pengangkut/ pengirim barang/ pengirim bertanggung jawab untuk memastikan kemasan, label, dan

penandaan yang sesuai dengan jenis transportasi yang digunakan.

Transpor jalan

Bukan barang berbahaya

Transpor laut (IMDG/IMO)

Bukan barang berbahaya

BAGIAN 15. INFORMASI YANG BERKAITAN DENGAN REGULASI

LEMBARAN DATA KESELAMATAN BAHAN

ECO PINE NF

907519

9 / 9

Regulasi domestik

Sistem Harmonisasi Global Klasifikasi dan Label Pada Bahan Kimia (87/M-IND/PER/9/2009)

Komponen-komponen produk ini dilaporkan dalam inventorisasi berikut:

Inventaris TSCA Amerika Serikat :

belum ditentukan

Daftar Senyawa Domestik Kanada :

Produk ini mengandung komponen-komponen berikut yang tidak terdaftar pada daftar DSL atau daftar

NDSL Kanada.

Australia. Undang-undang (Pengkajian dan Pemberitahuan) Kimia Industri :

belum ditentukan

Selandia Baru. Inventaris Bahan Kimia (NZIoC), seperti yang diterbitkan oleh ERMA Selandia

Baru :

belum ditentukan

Jepang. ENCS - Inventaris Senyawa Kimia Yang Sudah Ada Dan Yang Baru :

belum ditentukan

Jepang. ISHL - Inventaris Senyawa Kimia (METI) :

belum ditentukan

Korea. Inventaris Bahan Kimia Yang Sudah Ada (KECI) :

belum ditentukan

Inventaris Bahan Kimia dan Senyawa Kimia Filipina (PICCS) :

belum ditentukan

Cina. Inventaris Senyawa Kimia yang Sudah Ada :

belum ditentukan

BAGIAN 16. INFORMASI LAIN

Tanggal penerbitan pertama

11.08.2016

Versi

Disiapkan oleh

Urusan peraturan

Perbahan-perubahan peraturan atau informasi kesehatan yang signifikan dalam revisi ini ditunjukkan

oleh batang di bagian sisi kiri MSDS.

Informasi yang diberikan dalam Lembar Data Keselamatan ini benar menurut pengetahuan, informasi,

dan keyakinan kami pada tanggal penerbitan. Informasi yang diberikan dimaksudkan hanya sebagai

pedoman untuk penanganan, penggunaan, pemprosesan, penyimpanan, pengangkutan,

pembuangan, dan pembebasan yang aman dan tidak boleh dianggap sebagai jaminan atau

spesifikasi mutu. Informasi hanya menyangkut bahan spesifik yang telah ditentukan dan dapat tidak

berlaku jika bahan tersebut digunakan sebagai campuran dengan bahan lain atau dalam proses lain

kecuali jika dinyatakan secara spesifik dalam tulisan.

15-2-2019

Safety of Yarrowia lipolytica yeast biomass as a novel food pursuant to Regulation (EU) 2015/2283

Safety of Yarrowia lipolytica yeast biomass as a novel food pursuant to Regulation (EU) 2015/2283

Published on: Thu, 14 Feb 2019 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on Yarrowia lipolytica yeast biomass as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is the dried and heat‐killed biomass of Yarrowia lipolytica, a yeast species that is widespread in nature and which can be found in the environment as well as in foods. The production process is sufficiently describ...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-2-2019

Bee protection: ANSES makes recommendations to strengthen the regulatory framework

Bee protection: ANSES makes recommendations to strengthen the regulatory framework

As part of the Government's action plan on plant protection products and reduced dependence on pesticides in agriculture, ANSES is today publishing the results of its expert appraisal and its recommendations to strengthen the regulatory framework for the protection of bees and other pollinating insects. The aim of these recommendations is to further reduce bee exposure to plant protection products.

France - Agence Nationale du Médicament Vétérinaire

5-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for spinosad

Evaluation of confirmatory data following the Article 12 MRL review for spinosad

Published on: Mon, 04 Feb 2019 The applicant Dow AgroSciences Ltd submitted a request to the competent national authority in the Netherlands to evaluate the confirmatory data that were identified for spinosad in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. The data gaps related to residue trials on globe artichokes, flowering brassica and the nature of residues in processed commodities were satisfactorily addressed. A new feedi...

Europe - EFSA - European Food Safety Authority EFSA Journal

2-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for imazamox

Evaluation of confirmatory data following the Article 12 MRL review for imazamox

Published on: Fri, 01 Feb 2019 The applicant BASF SE submitted a request to the competent national authority in France to evaluate the confirmatory data that were identified for imazamox in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, the applicant submitted new residue trials on rice. Since the number of trials was not sufficient, the data gap was considered only partially addressed. The remaining dat...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...

Europe - EFSA - European Food Safety Authority EFSA Journal

25-1-2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Published on: Thu, 24 Jan 2019 The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre‐evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain lev...

Europe - EFSA - European Food Safety Authority EFSA Journal

23-1-2019

ANSES recommends improving baby diaper safety

ANSES recommends improving baby diaper safety

Today, ANSES published its assessment of the risks of chemicals found in baby diapers. Based on tests conducted on disposable diapers and their use, the Agency’s assessment highlighted several chemicals for which safety threshold values were exceeded. With regard to the possible risks of these chemicals to baby health, ANSES recommends eliminating these latter or reducing their levels as much as possible in disposable diapers.

France - Agence Nationale du Médicament Vétérinaire

22-1-2019

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Isagro S.p.A submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) for the active substance tetraconazole in various crops and animal commodities. The data submitted in support of the request were found to be sufficient to derive MRL proposals for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds. Adequate analytical me...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Genotoxicity assessment of chemical mixtures

Genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Guidance on Communication of Uncertainty in Scientific Assessments

Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Software for Benchmark Dose Modelling

Software for Benchmark Dose Modelling

Published on: Mon, 14 Jan 2019 In specific contract No 7 issued under the framework agreement OC/EFSA/AMU/2015/02, EFSA requested Open Analytics to extend the Web application for Benchmark Dose Modelling built under specific contracts No 3 and No 4. The Web application is further developed in R with focus on creating a graphical module to evaluate model fit and to modify specific plot settings, as specified in the Technical Annex to Specific Contract No 7. The web application includes the latest develop...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for rabbits for fattening. HOSTAZYM® X contains endo‐1,4‐beta‐xylanase produced by a strain of Trichoderma citrinoviride and is available in liquid and solid formulations. It is authorised as a feed additive for chickens for fattening, turkeys f...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Monitoring sales of veterinary antimicrobials

Monitoring sales of veterinary antimicrobials

Veterinary antimicrobial sales have been monitored annually by the Agency since 1999. This monitoring is based on the recommendations in Chapter 6.8 of the OIE's 2016 Terrestrial Animal Health Code "Monitoring of the quantities and usage patterns of antimicrobial agents used in food-producing animals".

France - Agence Nationale du Médicament Vétérinaire

22-12-2018

Modification of the existing maximum residue level for captan in hops

Modification of the existing maximum residue level for captan in hops

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Pest categorisation of Cronartium spp. (non‐EU)

Pest categorisation of Cronartium spp. (non‐EU)

Published on: Wed, 19 Dec 2018 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Cronartium spp. (non‐EU), a well‐defined and distinguishable group of fungal pathogens of the family Cronartiaceae. There are at least 40 species described within the Cronartium genus, of which two are considered native to the EU (C. gentianeum and C. pini) and one has been introduced in the 19th century (C. ribicola) and is now widespread in the EU – these t...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-12-2018

Giant Tiger recalls 6.5 foot Pre-Lit Noble Pine Tree

Giant Tiger recalls 6.5 foot Pre-Lit Noble Pine Tree

Some trees may have been sold with a 12V adaptor, not a 5V adaptor as intended. When the 12V adaptor is used it can cause the lights to overheat, posing a fire hazard.

Health Canada

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce E. coli O157:H7 outbreak investigation

FDA - U.S. Food and Drug Administration

12-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

FDA releases guidance with recommendations for drug manufacturers regarding good manufacturing practices and data integrity

FDA - U.S. Food and Drug Administration

8-2-2019

Zyprexa Velotab (Eli Lilly Nederland B.V.)

Zyprexa Velotab (Eli Lilly Nederland B.V.)

Zyprexa Velotab (Active substance: Olanzapine) - Centralised - Yearly update - Commission Decision (2019)1038 of Fri, 08 Feb 2019

Europe -DG Health and Food Safety

6-2-2019

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations:  https://go.usa.gov/xENj4  #MedicalDevicepic.twitter.com/szwLQ8FvxA

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4  #MedicalDevicepic.twitter.com/szwLQ8FvxA

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4  #MedicalDevice pic.twitter.com/szwLQ8FvxA

FDA - U.S. Food and Drug Administration

5-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Adasuve,loxapine, decision type: , therapeutic area: , PIP number: P/0295/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adasuve,loxapine, decision type: , therapeutic area: , PIP number: P/0295/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adasuve,loxapine, decision type: , therapeutic area: , PIP number: P/0295/2018

Europe - EMA - European Medicines Agency

4-2-2019

Olanzapine Glenmark (Glenmark Arzneimittel GmbH)

Olanzapine Glenmark (Glenmark Arzneimittel GmbH)

Olanzapine Glenmark (Active substance: Olanzapine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)853 of Mon, 04 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/1085/T/29

Europe -DG Health and Food Safety

4-2-2019

Olanzapine Glenmark Europe (Glenmark Arzneimittel GmbH)

Olanzapine Glenmark Europe (Glenmark Arzneimittel GmbH)

Olanzapine Glenmark Europe (Active substance: Olanzapine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)856 of Mon, 04 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/1086/T/27

Europe -DG Health and Food Safety

31-1-2019

Today @US_FDA issued a safety communication to providers and patients  about the risks of air-in-line when using infusion pumps, rapid  infusers, and fluid warmers. Find out more about the risks and #FDA  recommendations:  https://go.usa.gov/xE9g7  ##Medi

Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7  ##Medi

Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7  # #MedicalDevice pic.twitter.com/lLIyoG6680

FDA - U.S. Food and Drug Administration

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Europe - EMA - European Medicines Agency

4-1-2019


New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

Europe - EMA - European Medicines Agency

19-12-2018

EU/3/15/1545 (Seagen Ireland Limited)

EU/3/15/1545 (Seagen Ireland Limited)

EU/3/15/1545 (Active substance: CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug) - Transfer of orphan designation - Commission Decision (2018)9039 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002611

Europe -DG Health and Food Safety

19-12-2018


Recommendations on eligibility to PRIME scheme -  Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Europe - EMA - European Medicines Agency